NASDAQ:VSTM Verastem (VSTM) Stock Price, News & Analysis $4.05 +0.14 (+3.58%) (As of 11/26/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Verastem Stock (NASDAQ:VSTM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Verastem alerts:Sign Up Key Stats Today's Range$3.92▼$4.2450-Day Range$2.61▼$4.4652-Week Range$2.10▼$14.22Volume781,447 shsAverage Volume596,581 shsMarket Capitalization$180.27 millionP/E RatioN/ADividend YieldN/APrice Target$12.50Consensus RatingBuy Company OverviewVerastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.Read More… The Great AI-Energy Collision (Ad)The biggest players in AI and tech are desperate to bring this limitless power source online. And fast. It’s the only way they can compete in their race for AI dominance. A handful of energy stocks are going to emerge from this transformation to dominate the sector. Get the full story here, while you still can. Verastem Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks58th Percentile Overall ScoreVSTM MarketRank™: Verastem scored higher than 58% of companies evaluated by MarketBeat, and ranked 422nd out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVerastem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVerastem has only been the subject of 4 research reports in the past 90 days.Read more about Verastem's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Verastem are expected to grow in the coming year, from ($3.16) to ($2.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verastem is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verastem is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerastem has a P/B Ratio of 1.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Verastem's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.06% of the float of Verastem has been sold short.Short Interest Ratio / Days to CoverVerastem has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Verastem has recently increased by 0.82%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerastem does not currently pay a dividend.Dividend GrowthVerastem does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.06% of the float of Verastem has been sold short.Short Interest Ratio / Days to CoverVerastem has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Verastem has recently increased by 0.82%, indicating that investor sentiment is decreasing. News and Social Media3.1 / 5News Sentiment0.58 News SentimentVerastem has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Verastem this week, compared to 3 articles on an average week.Search Interest9 people have searched for VSTM on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat Follows3 people have added Verastem to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,271.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of Verastem is held by insiders.Percentage Held by Institutions88.37% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verastem's insider trading history. Receive VSTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter. Email Address VSTM Stock News HeadlinesVerastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx ConferenceNovember 26 at 7:00 AM | businesswire.comVerastem Inc. Reports Increased Operating Expenses and Net LossNovember 22, 2024 | markets.businessinsider.comThe Great AI-Energy CollisionThe biggest players in AI and tech are desperate to bring this limitless power source online. And fast. It’s the only way they can compete in their race for AI dominance. A handful of energy stocks are going to emerge from this transformation to dominate the sector. November 26, 2024 | Porter & Company (Ad)Verastem (NASDAQ:VSTM) Cut to "Sell" at StockNews.comNovember 22, 2024 | americanbankingnews.comAnalysts Set Verastem, Inc. (NASDAQ:VSTM) Price Target at $14.57November 20, 2024 | americanbankingnews.comOrbiMed Advisors LLC's Strategic Acquisition of Verastem Inc SharesNovember 15, 2024 | gurufocus.comVerastem price target lowered to $14 from $20 at Alliance Global PartnersNovember 7, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on Verastem (VSTM)November 7, 2024 | markets.businessinsider.comSee More Headlines VSTM Stock Analysis - Frequently Asked Questions How have VSTM shares performed this year? Verastem's stock was trading at $8.14 at the beginning of 2024. Since then, VSTM shares have decreased by 50.2% and is now trading at $4.05. View the best growth stocks for 2024 here. How were Verastem's earnings last quarter? Verastem, Inc. (NASDAQ:VSTM) posted its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.11. When did Verastem's stock split? Verastem shares reverse split on the morning of Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. Who are Verastem's major shareholders? Verastem's top institutional shareholders include Stonepine Capital Management LLC (2.94%), Geode Capital Management LLC (2.00%), State Street Corp (0.95%) and Walleye Capital LLC (0.49%). Insiders that own company stock include Dan Paterson, Brian M Stuglik, Daniel Calkins and Robert E Gagnon. View institutional ownership trends. How do I buy shares of Verastem? Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Verastem own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verastem investors own include TherapeuticsMD (TXMD), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU) and Gilead Sciences (GILD). Company Calendar Last Earnings11/06/2024Today11/26/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/13/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:VSTM CUSIP92337C10 CIK1526119 Webwww.verastem.com Phone(781) 292-4200FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$12.50 High Stock Price Target$20.00 Low Stock Price Target$7.00 Potential Upside/Downside+203.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,370,000.00 Net MarginsN/A Pretax Margin-934.54% Return on Equity-332.73% Return on Assets-73.97% Debt Debt-to-Equity Ratio2.77 Current Ratio3.23 Quick Ratio3.23 Sales & Book Value Annual Sales$2.60 million Price / Sales70.53 Cash FlowN/A Price / Cash FlowN/A Book Value$2.27 per share Price / Book1.81Miscellaneous Outstanding Shares44,510,000Free Float43,528,000Market Cap$183.38 million OptionableOptionable Beta0.14 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:VSTM) was last updated on 11/26/2024 by MarketBeat.com Staff From Our PartnersIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | Sponsored140% Yields From Stocks Like Tesla? Here's How (Black Friday Special)140% Dividends from stocks like Tesla? Discover How for Just $9! For Black Friday, get the full details of ...Investors Alley | Sponsored9 hidden AI stocks set to thrive in Trump’s new eraAI ETFs are Booming, But These 9 AI Stocks are Better Plays By 2030, the AI industry is projected to be wor...StockEarnings | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored❗[Investor Alert] Under-the-Radar TechWhile most investors are caught up in cryptocurrencies, AI stocks, or Jim Cramer's latest "hot pick…" One c...TuneGO | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.